Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When you see a stock with such a low float trading millions and millions of shares, you can bet there are a lot of folks day trading the crap out of this stock.
I just sit back and watch the show with my small shares.
Interesting. The stock rarely trades, you create a thread the VERY SAME DAY that the stock has massive volume with no news.
The SEC watches this kind of stuff like I do. Very easy to find.
The company probably thanks you for letting them fund their operations. I imagine they were very busy Friday, not with their business, but selling shares.
What a windfall, a bunch of knuckleheads on some innernut stock sites make a massive Friday pump.
PT > $15.00 > Oppenheimer analyst Hartaj Singh initiates coverage on Spruce Biosciences (NASDAQ:SPRB) with a Outperform rating and announces Price Target of $15.
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for rare endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a potent and selective, non-steroidal, oral, small-molecule antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is a regulator of the production of adrenocorticotropic hormone (ACTH). Its CAHmelia-203, is a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with CAH with poor disease control. Its CAHmelia-204, is a second Phase IIb clinical trial in adult patients with CAH with good disease control focused on glucocorticoid reduction. It has also conducted two Phase IIa clinical trials of tildacerfont in adult patients with CAH on stable glucocorticoid therapy.